Clinical Trial Update: Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia. [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing the safety and tolerability of sotatercept (ACE-011) in adults with beta-thalassemia was terminated; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta Thalassemia Major
• Beta-thalassemia
• Beta-thalassemia Intermedia

Drugs mentioned

• Sotatercept (sotatercept)

Snippet

Sponsor: Celgene | Conditions: Beta Thalassemia Major, Beta Thalassemia Intermedia | Phase 2 | Status: TERMINATED | Results posted: 2023-06-18